Incyte | INCY - Capitaux D'Emprunt





Capitaux D'Emprunt Changement Date
Acadia Pharmaceuticals USD 0 0 2025-03
Agenus USD 169.66M 146.06M 2025-12
Agios Pharmaceuticals USD 1.06M 0 2022-09
Alnylam Pharmaceuticals USD 2.48B 931K 2026-03
Amgen USD 51.89B 1.88B 2026-03
BioCryst Pharmaceuticals USD 395.2M 33.48M 2026-03
Biogen USD 6.29B 1.7M 2026-03
BioMarin Pharmaceutical USD 1.43B 833.11M 2026-03
Bristol-Myers Squibb USD 42.15B 698M 2026-03
Eli Lilly USD 39.37B 1.5B 2026-03
Gilead Sciences USD 20.86B 1.27B 2026-03
Incyte USD 29.41M 785K 2026-03
Ionis Pharmaceuticals USD 1.91B 9M 2026-03
MacroGenics USD 70M 256K 2025-12
Merck USD 46.67B 77M 2026-03
Moderna USD 603M 7M 2026-03
Nektar Therapeutics USD 63.16M 44.35M 2025-12
Neurocrine Biosciences USD 169.5M 500K 2023-03
Novartis USD 37.45B 7.86B 2026-03
Novartis USD 29.59B 5.35B 2025-12
Pfizer USD 60.57B 1.08B 2026-03
PTC Therapeutics USD 286.94M 1.74B 2026-03
Puma Biotechnology USD 10.87M 222K 2025-06
Regeneron Pharmaceuticals USD 1.99B 719.7M 2026-03
Sarepta Therapeutics USD 838.16M 9.19M 2026-03
Ultragenyx Pharmaceutical USD 1.13B 19M 2026-03
Vertex Pharmaceuticals USD 106.7M 4.7M 2025-12